XENE
XenonCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-03
+
Peers tracked
11
U.S. public peers
Grade Position
Below peers
vs peer average
XENE vs peer average
39/100
XENE vs. peer average (C vs. B)
Grade spread
A 1 · B 5 · C 2 · D 1
Graded peers loaded
Coverage
10 graded
91% of tracked
Peer overview
APLS is the first available peer comparator.
Apellis is a useful mid-cap biotech comparator for how late-stage clinical success can already be capitalized into valuation before regulatory and commercial execution are complete, though the therapeutic overlap is limited.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
XENE
Xenon
APLS
Peer
Grade
C
-
Momentum
55
-
Value
41
-
Sentiment
55
-
Setup Bias
Net Neutral
-
Market Cap
-
-
Posture
Mixed
Unrated
Grade position vs APLS
XENE / APLS
Grade Position
Below peers
XENE vs. peer average (C vs. B)
39/100
Momentum
55
-Value
41
-Sentiment
55
-Rotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs XENE
APLS is the first peer returned for this comparison set.